Top-Rated Stocks NASDAQ:DNLI Denali Therapeutics - DNLI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $23.04 +1.13 (+5.16%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$21.96▼$23.1150-Day Range$21.91▼$32.6752-Week Range$20.24▼$39.43Volume1.10 million shsAverage Volume684,416 shsMarket Capitalization$3.15 billionP/E RatioN/ADividend YieldN/APrice Target$54.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Denali Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.9% Upside$54.58 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2.69 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.48) to ($3.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector72nd out of 1,004 stocksBiological Products, Except Diagnostic Industry13th out of 166 stocks 4.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.58, Denali Therapeutics has a forecasted upside of 136.9% from its current price of $23.04.Amount of Analyst CoverageDenali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DNLI. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 2.9 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Denali Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows8 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,689,975.00 in company stock.Percentage Held by Insiders12.70% of the stock of Denali Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.26% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($3.48) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Denali Therapeutics (NASDAQ:DNLI) StockDenali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.Read More Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesMarch 29, 2023 | finance.yahoo.comWhy Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?March 4, 2023 | finance.yahoo.comThe Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell DramaticallyApril 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 2, 2023 | markets.businessinsider.comWhere Denali Therapeutics Stands With AnalystsMarch 1, 2023 | finanznachrichten.deDenali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Denali Therapeutics (DNLI)February 27, 2023 | finance.yahoo.comDenali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | msn.comDenali Therapeutics GAAP EPS of -$0.75 beats by $0.03, revenue of $10.28M misses by $1.01MApril 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...February 24, 2023 | marketwatch.comDenali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium (TM)February 23, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Denali Therapeutics (DNLI)February 23, 2023 | finance.yahoo.comDenali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome StudyFebruary 22, 2023 | finance.yahoo.comDenali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™February 21, 2023 | finance.yahoo.comHeska (HSKA) Earnings Expected to Grow: Should You Buy?February 15, 2023 | finance.yahoo.comDenali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™January 30, 2023 | markets.businessinsider.comExpert Ratings for Denali TherapeuticsJanuary 25, 2023 | finance.yahoo.comDenali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by SanofiJanuary 16, 2023 | seekingalpha.comDenali: Need Patient Data To Justify That High ValuationJanuary 2, 2023 | finance.yahoo.comWith 63% ownership, Denali Therapeutics Inc. (NASDAQ:DNLI) boasts of strong institutional backingDecember 13, 2022 | finance.yahoo.comLet's Take a Technical Peek at Denali TherapeuticsDecember 6, 2022 | finance.yahoo.comWe're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn RateDecember 5, 2022 | baystreet.caDenali Slumps on Drug Candidate TestsDecember 5, 2022 | technews.tmcnet.comDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialDecember 5, 2022 | finance.yahoo.comDenali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform TrialNovember 9, 2022 | finance.yahoo.comDenali Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsNovember 4, 2022 | finance.yahoo.comDenali (DNLI) Lags Q3 Earnings Estimates, Pipeline in FocusNovember 4, 2022 | finance.yahoo.comDenali Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Company Calendar Last Earnings2/27/2023Today3/31/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees380Year Founded2015Price Target and Rating Average Stock Price Forecast$54.58 High Stock Price Forecast$105.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+136.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,990,000.00 Net Margins-300.55% Pretax Margin-300.54% Return on Equity-35.67% Return on Assets-24.60% Debt Debt-to-Equity RatioN/A Current Ratio3.77 Quick Ratio3.77 Sales & Book Value Annual Sales$108.46 million Price / Sales29.03 Cash FlowN/A Price / Cash FlowN/A Book Value$7.68 per share Price / Book3.00Miscellaneous Outstanding Shares136,680,000Free Float119,320,000Market Cap$3.15 billion OptionableOptionable Beta1.39 Social Links Key ExecutivesRyan J. WattsPresident, Chief Executive Officer & DirectorAlexander O. SchuthSecretary, Chief Operating & Financial OfficerCarole HoChief Medical Officer & Head-DevelopmentDana AndersenCTO & Chief Manufacturing OfficerJoe LewcockChief Scientific OfficerKey CompetitorsAbcamNASDAQ:ABCMVir BiotechnologyNASDAQ:VIRVaxcyteNASDAQ:PCVXCRISPR TherapeuticsNASDAQ:CRSPGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsMetropolitan Life Insurance Co. NYBought 780 shares on 3/31/2023Ownership: 0.005%MetLife Investment Management LLCBought 4,600 shares on 3/23/2023Ownership: 0.042%Rockefeller Capital Management L.P.Sold 1,976 shares on 3/6/2023Ownership: 0.007%Voya Investment Management LLCBought 4,054 shares on 2/28/2023Ownership: 0.120%Teachers Retirement System of The State of KentuckyBought 29,304 shares on 2/22/2023Ownership: 0.152%View All Insider TransactionsView All Institutional Transactions DNLI Stock - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price forecast for 2023? 13 analysts have issued 12 month price objectives for Denali Therapeutics' shares. Their DNLI share price forecasts range from $32.00 to $105.00. On average, they expect the company's share price to reach $54.58 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2023? Denali Therapeutics' stock was trading at $27.81 at the beginning of 2023. Since then, DNLI stock has decreased by 17.2% and is now trading at $23.04. View the best growth stocks for 2023 here. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Monday, February, 27th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.02. The company earned $10.28 million during the quarter, compared to analyst estimates of $11.29 million. Denali Therapeutics had a negative net margin of 300.55% and a negative trailing twelve-month return on equity of 35.67%. The business's revenue was down 17.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include Psyk Etf (PSYK), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. What is Denali Therapeutics' stock symbol? Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI." How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Denali Therapeutics' stock price today? One share of DNLI stock can currently be purchased for approximately $23.04. How much money does Denali Therapeutics make? Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.15 billion and generates $108.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. How many employees does Denali Therapeutics have? The company employs 380 workers across the globe. How can I contact Denali Therapeutics? Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com. This page (NASDAQ:DNLI) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.